Serum 25(OH) Vitamin D Concentration Changes After Roux-en-Y Gastric Bypass Surgery

Lauren M. Beckman,1 Carrie P. Earthman,1,* William Thomas,2 Charlene W. Compher,3 Juan Muniz,3 Ronald L. Horst,4 Sayeed Ikramuddin,5 Todd A. Kellogg5 and Shalamar D. Sibley6

Objective: To describe serum 25(OH)D changes after Roux-en-Y gastric bypass (RYGB) and to determine if fat mass (FM) loss and vitamin D intake are associated with changes in serum levels.

Design and Methods: The relationship between serum 25(OH)D and 1) FM, 2) weight, 3) % excess weight loss (EWL), and 4) BMI was investigated after controlling for potential confounders using a mixed effects linear model in 20 women before and up to 1-year post-RYGB. Subcutaneous (SAT) and visceral adipose tissue (VAT) vitamin D concentrations at time of RYGB were also evaluated.

Results: Weight and FM decreased 1-year after surgery by 45±1 kg and 37±1 kg, respectively while 25(OH)D increased by 10±2 ng mL⁻¹. Weight, FM, BMI, and %EWL changes were associated with 25(OH)D change. VAT had an average 21% more vitamin D per gram than SAT and concentrations were highly correlated.

Conclusions: Although weight loss may lead to increased serum 25(OH)D after RYGB, low levels remain a concern in some patients 1-year postsurgery. Additional research is needed to clarify the relationship between adipose storage of vitamin D and serum 25(OH)D in obesity, and how that relationship might change after surgery. This could lead to improved clinical management of vitamin D in this ever-growing clinical population.

Introduction

The worldwide obesity epidemic is associated with numerous conditions of public health concern, including low vitamin D levels (1). Serum 25-hydroxyvitamin D (25(OH)D) levels <30 ng mL⁻¹ and <20 ng mL⁻¹ were previously used to define vitamin D insufficiency and deficiency, respectively (2), but recently the Institute of Medicine (IOM) redefined deficiency to <12 ng mL⁻¹ based upon bone health indicators (3). The IOM also redefined serum 25(OH)D concentrations from 12 to 19 ng mL⁻¹ as inadequate; 20-29 ng mL⁻¹ is the old definition. In contrast, the Endocrine Society Guidelines (4) have recently advised that the lower end of the acceptable range should be 30 ng mL⁻¹ based on the study by Priemel et al. (5), which demonstrated asymptomatic osteomalacia between serum 25(OH)D levels of 20-30 ng mL⁻¹. For the purposes of consistency we will adhere to the new IOM guidelines.

It is well-documented that obese individuals have relatively low vitamin D levels (6,7). Moreover, BMI (8), body weight (8), and fat mass (FM) (8,9) are inversely related to serum 25(OH)D levels. The potential health ramifications of this observation are many, given the association between low vitamin D status and risk for metabolic syndrome (10), hypertension (11), and some cancers (11). Given that obese individuals are at risk for these comorbidities, it is necessary to better understand the causes for and potential solutions to the problem of low vitamin D status in this population.

High obesity prevalence has resulted in growing numbers of bariatric surgeries worldwide (12). The Roux-en-Y gastric bypass (RYGB) is the most common bariatric surgery and is considered the most effective for long-term weight loss (13). A recent meta-analysis (14) reported that the average weight loss post-RYGB is ~45 kg. A substantial amount of this weight loss is FM, with studies reporting losses of 6.9 kg (15) to 35.9 kg (16) one (15) to 24 (16) months...
post-RYGB, making this a unique population in which to study vitamin D changes, considering that it is a fat soluble vitamin. However, prospective data on the effect of FM loss on vitamin D levels post-RYGB are lacking. The majority of studies have only evaluated vitamin D in relation to weight status preoperatively (17) or postoperatively in light of BMI and weight (but not body composition) changes (18-22). More comprehensive evaluations of FM loss in relation to change in circulating 25(OH)D concentration are needed. Another limitation of many prospective studies is that quantification of vitamin D intake is not always included (18-20,22) or the methods are incompletely described (17).

Our objective was to describe post-RYGB serum 25(OH)D changes and to determine if FM loss and vitamin D intake are associated with these changes up to 1 year after surgery. An additional objective was to measure vitamin D concentrations in two adipose tissue depots, VAT and SAT, at the time of RYGB. We hypothesized the following: (1) after RYGB, serum 25(OH)D levels would increase; (2) anthropometric changes (decrease in FM, body weight, and BMI, and percent excess weight loss (%EWL)) would be associated with increased serum 25(OH)D levels; and (3) VAT and SAT would both contain comparable concentrations of vitamin D.

Methods and Procedures

Twenty-nine women undergoing the laparoscopic RYGB procedure were recruited from the University of Minnesota’s Weight Loss Surgery Center. This study included five visits: 30-70 days pre-RYGB (Baseline); 2-weeks post-RYGB (week 2); 6 weeks post-RYGB (week 6); 6-months post-RYGB (week 24); and 1 year post-RYGB (week 52). The study visit schedule allowed for the evaluation of early (e.g., weeks 2 and 6) and late (e.g., weeks 24 and 52) postoperative outcomes. Exclusion criteria included: use of corticosteroids, testosterone, or anabolic agents; pacemaker; liver, renal, or heart failure; pulmonary hypertension; untreated thyroid disease; cancer; Type 1 or uncontrolled Type 2 diabetes mellitus (defined by HbA1c >7%); pregnancy; and/or previous weight loss surgery. The study protocol was approved by the Institutional Review Board and the General Clinical Research Center (GCRC) at the University of Minnesota. Subjects provided written, informed consent before participating.

Serum 25(OH)D assay

A fasting blood sample was collected at each visit and serum was frozen at −70°C until assay using the Diasorin Liaison total 25(OH)D assay method (Diasorin, Stillwater, MN). This method uses a two-step competitive chemiluminescence (CLIA) assay with a unique antibody to 25OH D2 and D3, allowing for determination of total serum 25(OH)D. The method detects a sample concentration range of 4-150 ng mL⁻¹ with analytical sensitivity <1 ng mL⁻¹. Samples were assayed in duplicate, with mean value recorded.

Vitamin D2 and D3 assay of intraoperative adipose and Pre-RYGB serum

For the purposes of describing serum and adipose depot vitamin D concentrations, an additional baseline serum sample was analyzed for vitamin D2 and D3 by NMS Laboratories (Willow Grove, PA) using LC-MS-MS. During the RYGB procedure, abdominal subcutaneous (SAT) and visceral (VAT) compartment adipose tissue samples were collected by the surgeon (<10 g in total). Briefly, a subcutaneous adipose sample was extracted through a linear incision in the abdominal wall using scissors and electrocautery. A visceral adipose sample was taken from the greater omentum coming off the transverse colon using a harmonic scalpel. Samples were quick frozen in liquid nitrogen and then stored at −70°C until assay.

Adipose vitamin D2 and vitamin D3 concentrations were analyzed using a high-performance liquid chromatography (HPLC) method developed at Heartland Assays, LLC for food (23) and modified for the measurement of vitamin D2 and D3 in adipose tissue. The adipose samples were first saponified in methanolic KOH. The sample was spiked with an internal standard [¹³C]-vitamin D₃, (30 Curies mmole⁻¹) to estimate recovery losses. After 60 min at 60°C the saponified material was extracted three times with 1 vol. of hexane-ethyl acetate (85/15). The extract was washed with water, collected and dried under vacuum. The dried extract was re-suspended in 1.0 ml of hexane/methylene chloride 90/10 v/v, applied to a hand packed solid-phase extraction cartridge, eluted with methylene chloride/2-propanol (99.8/0.2) and dried. The residue was re-suspended in hexane/methylene chloride/ethanol (85/15/0.2), and applied to Agilent HPLC ZORBAX SIL column, and the vitamin D fraction was collected, and dried. The residue was re-suspended in hexane/ethanol (99.5/0.5), and again applied to an HPLC ZORBAX NH₂ column, and the vitamin D fraction was collected and dried for final purification. The final purification for vitamin D2 and vitamin D3 by HPLC was achieved using a Vydrac ODS column. Vitamin D₂ and vitamin D₃ were quantified by comparison of the UV peak areas with known standards and corrected for recovery. Vitamin D₂ is baseline resolved from Vitamin D₃. Method validation consisted of addition of 60 ng of both vitamin D₂ and vitamin D₃ plus [3H]-vitamin D₃ to 10 fat samples. Average recovery of the vitamin D₂ and vitamin D₃ was 98.5% ± 5%.

Dietary intake assessment

Information regarding dietary and supplemental vitamin D intake was obtained at each visit through the use of diet records. During the week prior to each testing visit, subjects recorded their food, beverage, and vitamin/mineral supplement intake on two assigned weekdays and one weekend day. Recording errors were minimized by providing the subjects with detailed verbal and written instructions on how to record their intake, including estimation of portion size using food models, measuring cups and spoons for illustration purposes. Diet records were reviewed at each testing visit and subjects were queried for missing details regarding condiments and cooking methods. Data were analyzed using the Food Processor software (SQL edition, version 10.4 ESHA Research, Salem, OR). To estimate daily vitamin D intake during the week prior to the visit, an average of the recorded intake was calculated.

Anthropometric measurements

Height was measured to the nearest 0.1 cm by a wall-mounted stadiometer (model S100; AYRTON, Prior Lake, MN) at baseline only. At all testing visits, weight was measured to the nearest 0.1 kg on a digital scale (model 5002, SCALE-TRONIX, White Plains, NY). Body mass index (BMI) was calculated as body weight/height² (kg m⁻²). Percent excess weight loss (%EWL) was calculated using the following equation:
TABLE 1 Subject characteristics

|                      | Pre-RYGB (n = 20) | Week 2 (n = 17) | Week 6 (n = 20) | Week 26 (n = 20) | Week 52 (n = 20) |
|----------------------|-------------------|----------------|----------------|----------------|----------------|
| Age (years)          | 48 ± 2            | 125 ± 4        | 118 ± 4        | 98 ± 4         | 88 ± 4         |
| Body weight (kg)     | 132 ± 4           | 125 ± 4        | 118 ± 4        | 98 ± 4         | 88 ± 4         |
| Body weight change (kg) | -7 ± 1           | -14 ± 1        | -35 ± 1        | -45 ± 1        | -45 ± 1        |
| BMI (kg m⁻²)         | 48 ± 1            | 45 ± 1         | 43 ± 1         | 35 ± 1         | 32 ± 1         |
| Fat mass (kg)        | 69 ± 3            | 67 ± 3         | 61 ± 3         | 42 ± 3         | 32 ± 3         |
| Fat mass change (kg) | -2 ± 2            | -8 ± 1         | -28 ± 1        | -37 ± 1        | -37 ± 1        |
| Serum 25(OH)D (ng mL⁻¹) | 19 ± 2           | 22 ± 2         | 25 ± 2         | 24 ± 2         | 20 ± 2         |
| Serum 25(OH)D change (ng mL⁻¹) | 3 ± 2      | 6 ± 2          | 6 ± 2          | 5 ± 2          | 10 ± 2         |
| Dietary/supplemental vitamin D intake (IU) | 129 (71-235) | 352 (180-687)² | 602 (325-1114)ᶜ | 558 (306-1018)ᶜ | 417 (229-760)ᵇ |

Notes: ²Significantly different from Pre-RYGB at P < 0.05. ʳSignificantly different from Pre-RYGB at P < 0.01. ᶜSignificantly different from Pre-RYGB at P < 0.001. ᵇFor 25OH-D, n = 19.

Abbreviations: RYGB: Roux-en-Y gastric bypass; 25(OH)D: 25 hydroxyvitamin D. Note: Unless otherwise noted, data are Mean ± SEM.

Ideal body weight was determined from the Metropolitan Life Weight Tables. The middle weight of the range for a medium framed woman was used for all IBW calculations.

Total body water measurement

Total body water (TBW) was determined by deuterium dilution, as previously described (24). Briefly, a fasted baseline urine sample was collected prior to initiation of the dilution protocol at 7 am of Day 2. A weighed dose of deuterium oxide (99.9 atom %; Isotec, Miamisburg, OH) providing 0.1 g kg⁻¹ body weight was IV pushed over a 5-min period. The syringe containing the deuterium oxide was weighed before and after administration to determine the precise amount that was administered to the subject. Hourly urine samples were collected, as well as a final urine sample at 4-h postinfusion. All urine samples were tightly sealed, packed on dry ice, and stored at −70°C until analysis. Baseline, and 3- and 4-h postdose urine samples were shipped to Michael Jensen’s laboratory at the Mayo Clinic (Rochester, MN) for analysis. TBW was calculated from the average deuterium enrichment of the 3- and 4-h urine samples and then reduced by 4% to correct for exchange with the nonaquous compartment (25).

Fat mass determination

FM was determined using body weight and fat-free mass (FFM) (calculated using TBW measurements). FM was estimated by:

\[
FM = \text{Body weight-FFM} = \frac{\text{Body weight-TBW}}{0.73},
\]

where 0.73 is the standard hydration coefficient of FFM (25).

Results

Twenty of 29 women completed at least four study visits. Baseline BMI and FM values were significantly greater in those who...
Vitamin D Concentration After Gastric Bypass

TABLE 2 Baseline average vitamin D2 and vitamin D3 in SAT, VAT, and serum and serum 25(OH)D (n = 13)

| Location of sample | Vitamin D2 | Vitamin D3 | Total vitamin D | 25(OH)D |
|-------------------|------------|------------|----------------|---------|
| SAT (ng g⁻¹)      | 10 ± 8     | 29 ± 9     | 38 ± 11        |         |
| VAT (ng g⁻¹)      | 13 ± 10    | 36 ± 10²   | 48 ± 14²       |         |
| Serum (ng mL⁻¹)   | 0.7 ± 0.5  | 33 ± 4     | 34 ± 4         | 21 ± 2  |

²Significantly different than SAT (P < 0.01): Mean ± SEM.

Abbreviation: 25(OH)D: 25 hydroxyvitamin D; SAT: subcutaneous adipose tissue; VAT: visceral adipose tissue.

completed the study (n = 20) compared to those who did not (n = 9). Three subjects did not attend the week 2 visit secondary to not feeling well after surgery and serum 25(OH)D analysis was not available for one subject at the week 52 visit due to insufficient sample collection.

Subjects for this analysis resided primarily in the Minneapolis/Saint Paul metropolitan area, which has a latitude of 44°59’ North. All participants were Caucasian with a mean age of 48 years. Body weight, BMI, FM, serum 25(OH)D, and dietary/supplemental vitamin D intake at baseline and subsequent study visits are presented in Table 1. One year after surgery, body weight, and FM decreased by 45 ± 1 kg and 37 ± 1 kg, respectively (P < 0.001) while serum 25(OH)D increased by 10 ± 2 ng mL⁻¹ (P < 0.001) (mean ± SEM) (Table 1). At baseline, serum 25(OH)D levels were all below 30 ng mL⁻¹ with 10 subjects <20 ng mL⁻¹ and by week 52, six subjects had levels greater than 30 ng mL⁻¹. Additionally, two subjects at Baseline and one at week 52 met the new serum 25(OH)D deficiency criteria of <12 ng mL⁻¹.

Seasonality and serum 25(OH)D

Serum 25(OH)D levels and change in serum 25(OH)D levels were analyzed for differences between seasons (Fall/Winter and Spring-Summer) at all testing visits. We were unable to detect a seasonal effect for either the absolute value or the change in serum 25(OH)D (P > 0.05) (data not shown).

Vitamin D2 and vitamin D3 in SAT, VAT, and Pre-RYGB serum

Vitamin D2 and vitamin D3 concentrations in intraoperative SAT and VAT and pre-RYGB serum are presented in Table 2. SAT and VAT vitamin D analyses were performed on 13 of the 29 subjects who completed the Baseline visit. While vitamin D3 was present in all adipose and serum samples, vitamin D2 was not always detected. VAT vitamin D3 and VAT total vitamin D (D2 and D3) concentrations were greater than that of SAT, by 19 and 21%, respectively (P < 0.01). In addition, SAT and VAT total vitamin D were highly correlated (R² = 0.99, P < 0.0001).

Change in serum 25OH vitamin D levels

In unadjusted correlations, change in serum 25(OH)D was positively correlated with change in body weight at week 26 (data not shown).

We then adjusted for potential influencing factors on serum 25OH vitamin D change, including vitamin D intake, age, and visit. Overall, a 10-kg loss of FM and body weight was associated with a 2.8 ± 1.3 ng mL⁻¹ (mean ± SEM; P = 0.04) and 3.9 ± 1.4 ng mL⁻¹ (P = 0.008) increase in serum 25(OH)D, respectively, controlling for aforementioned confounders (Table 3). Similarly, a one-unit reduction in BMI and a 10% change in EWL was associated with a 0.84 ± 0.4 ng mL⁻¹ (mean ± SEM; P = 0.04) and 2.1 ± 0.8 ng mL⁻¹ (P = 0.01) increase in serum 25(OH)D, respectively, controlling for the aforementioned confounders. Increased age was also significantly associated with decreased serum 25(OH)D in all four models (data not shown).

Discussion

In this study we evaluated serum 25(OH)D status before and after RYGB and investigated how FM and vitamin D intake are associated with this change. In addition, we described the vitamin D content of VAT and SAT at the time of RYGB. We found that low serum 25(OH)D levels are pervasive before RYGB with the mean level <20 ng mL⁻¹. The number of subjects with serum 25(OH)D levels <20 ng mL⁻¹ decreased within 1 year after RYGB and the mean level significantly increased from pre- to post-RYGB, with the 1-year group average of 29 ng mL⁻¹ falling above the new definition of adequate (>20 ng mL⁻¹). Changes in anthropometrics were positively associated with the change in serum 25(OH)D.

Serum 25(OH)D status before and after RYGB

Low circulating 25(OH)D levels were apparent before surgery and this is in line with data reported by other investigators in patients before RYGB (1,18,19,22). Although a significant concern, the low circulating 25(OH)D concentration observed before bariatric surgery is not surprising considering that this is a widespread phenomenon in individuals in this weight category (6,7). In fact, in a cross-sectional study by Goldner et al. (1), a higher prevalence of low 25(OH)D levels was found in pre-RYGB women compared to non-obese controls (61% vs. 12%, P < 0.0001). Vitamin and mineral supplements, including vitamin D are often prescribed following

TABLE 3 Model of change in serum 25(OH)D levels from baseline

| Effect                        | Change in serum 25(OH)D estimate (ng mL⁻¹) | Standard error | Pr > | t |
|-------------------------------|------------------------------------------|----------------|------|---|
| Fat mass change from baseline (10 kg) | 2.8                                      | 1.3            | 0.04 |   |
| Weight change from baseline (10 kg)   | 3.9                                      | 1.4            | 0.008|   |
| BMI change from baseline (1 kg m⁻² unit) | 0.84                                     | 0.4            | 0.04 |   |
| Percent EWL from baseline (10%)      | 2.1                                      | 0.8            | 0.01 |   |

Abbreviation: 25(OH)D: 25 hydroxyvitamin D; EWL: excess weight loss. Note: Models adjusted for age, vitamin D intake, and visit.
bariatric surgery, however our prevalence data and that of others indicate that routine supplementation of vitamin D should occur pre-operatively as well.

On average, subjects in our study experienced a modest increase in serum 25(OH)D concentrations after RYGB. This is in contrast to a recent study with similar methodology and subject number (17), in which a significant change was not observed at 1 year after RYGB. Of note, the study by Pramyothin et al. employed a more aggressive supplementation protocol with vitamin D2. It is somewhat surprising that we observed a significant increase in serum 25(OH)D concentrations despite lower vitamin D intake throughout the study, which otherwise had a similar overall design. Potential reasons for this discrepancy include differences in surgical technique and baseline subject characteristics, and compliance to and form of the vitamin D supplementation regimen (e.g., D2 vs. D3). Subjects in the study by Pramyothin et al. had higher average baseline vitamin D status (23 vs. 19 ng mL\(^{-1}\)) and reported vitamin D intake. Moreover, a majority of the subjects in our study were taking vitamin D3 supplements (compared to vitamin D2 in the Pramyothin study), which is known to be more effective at raising serum 25(OH)D levels. It should also be noted that, in the Pramyothin study, the dietary intake data were evaluated by self-report, and few additional protocol details were provided. This could have contributed error. In contrast, we obtained vitamin D intake data by employing a strict protocol utilizing 3-day dietary records that involved intensive subject training and review by dietitian-supervised staff.

Although we reported a significant overall increase in serum 25(OH)D concentration, not all subjects reached adequacy. In our study, about 85% of the subjects had serum 25(OH)D concentrations in the newly defined adequate range (\(\geq 20\) ng mL\(^{-1}\)) at week 52. Improved, yet persistently low 25(OH)D levels have been reported by others at 1 year or more after RYGB (16,19,27,28). A significant reduction in weight and FM occurred by 1 year after RYGB, and consequently we expected to see improved serum 25(OH)D levels in all subjects. However, despite significant reduction in adiposity, subjects in our study were still considered obese and for some individuals, perhaps not enough weight was lost to substantially impact the serum 25(OH)D concentration. We evaluated the BMI, weight loss, and FM loss data for the three subjects who did not achieve adequate serum 25(OH)D levels at week 52 (<20 ng mL\(^{-1}\)). All three were obese, but their weight and FM loss data was variable (range: 30-66 kg, 29-58 kg, respectively). Carlin et al., who reported low serum 25(OH)D levels (<20 ng mL\(^{-1}\)) post-RYGB, also had subjects that were classified as obese 12 months after RYGB (22). These observations support a role for more aggressive supplementation to facilitate optimization of serum 25(OH)D into the adequate range. Carlin et al. (22) prospectively evaluated vitamin D supplementation (unspecified if it was D2 or D3) and BMI status in 60 vitamin D deficient women before and after RYGB. Subjects were randomized to receive either (1) 50,000 IU vitamin D weekly and 800 IU vitamin D daily or (2) 800 IU vitamin D daily. BMI decreased in both groups after surgery (statistical significance not reported). Those in the high vitamin D supplement group, despite remaining obese at 1 year after RYGB, had serum 25(OH)D levels that were considered adequate by the new definition (mean = 38 ng mL\(^{-1}\)) and were 60% greater than the low supplement group (\(P < 0.001\) (mean = 15 ng mL\(^{-1}\)). Subjects in our study were advised by the Weight Loss Surgery Center to take a daily multi-vitamin after surgery (vitamin D content 400–800 IU), which is similar to that consumed by the low supplement group in the Carlin et al. study. Our finding of serum 25(OH)D levels <20 ng mL\(^{-1}\) in a small number of subjects (\(n = 3\)) 1 year after surgery would support the position that the level of vitamin D intake observed in our subjects is too low. In addition, our calculations suggest that FM vitamin D stores would not be able to support an 800 IU daily requirement in most subjects by 6-months post-RYGB. These findings further highlight the importance of vitamin D supplementation after RYGB and suggest that the frequently recommended daily dosage of 400-800 IU might not be sufficient for this patient population. Carlin et al. reported that the weekly dosage of 50,000 IU was safe, although additional research is needed to establish optimal dosing in this population. In addition, we cannot rule out the possibility that UVB exposure was likely not enough to promote adequate serum 25(OH)D levels, considering that production of vitamin D is only possible for a maximum of 7 months per year in Minnesota (29) and subjects were likely not exposing substantial areas of skin after surgery. Until more is known about the risk-benefit of sun exposure and vitamin D health we remain cautious about UVB exposure recommendations, but believe modest and safe exposure is essential for vitamin D health, especially in those with low vitamin D dietary/supplemental intake.

An alternative hypothesis for the low 25(OH)D levels observed in some subjects 1-year post-RYGB is that the surgery itself is contributory. Under normal physiological conditions, dietary vitamin D is absorbed in the proximal small intestine (30). During RYGB, the distal stomach, duodenum, and proximal jejunum are bypassed (31) resulting in micronutrient malabsorption, which could contribute to the insufficient 25(OH)D levels observed by ourselves and others (16,19,27,28). Of note, a recent report by Aarts et al. (32) demonstrated that a 25% reduction in vitamin D3 absorption occurred 1 month after RYGB despite supplementing with a single dose of 50,000 IU vitamin D3 during the postoperative period. A comparison between different bariatric surgeries (including RYGB, sleeve gastrectomy, duodenal switch) could better define the role of malabsorption in the low serum 25(OH)D levels seen after surgery. Unlike the RYGB, which is classically considered to have both malabsorptive and restrictive components and the duodenal switch which has an even more pronounced malabsorptive component, the adjustable gastric band (AGB) and sleeve gastrectomy procedures are purely restrictive weight loss surgeries, and micronutrient malabsorption would not be expected. Fish et al. (28) retrospectively compared vitamin D status between RYGB and AGB subjects for 2 years following surgery. Compared to AGB, the prevalence of serum 25(OH)D insufficiency (at the time, defined as <30 ng mL\(^{-1}\)) after RYGB was greater at 6 months (52% vs. 64%), 1 year (41% vs. 63%), and 2 years (50% vs. 73%) after surgery (statistical significance not reported for any time point). Similarly, Gehrer et al. (20) compared vitamin D status between RYGB and sleeve gastrectomy subjects and found higher incidence of low levels (serum 25(OH)D < 20 ng mL\(^{-1}\)) after RYGB (RYGB: 52%, sleeve gastrectomy: 32%, \(P = 0.02\)). Conversely, DiGiorgi et al. (19) did not find a difference between post-RYGB and post-AGB groups in serum 25(OH)D levels at 3, 6, 12, or 24 months after surgery and Coupay et al. (18) found significantly higher serum 25(OH)D levels 1 year after RYGB compared to AGB. High loss to follow-up (19) and small sample size (18) might explain the lack of consistent findings in these two studies. In sum, much is known about absorption of vitamin D in normal physiology (30), however the details on absorption after RYGB have yet to be fully elucidated. Consequently, well-designed vitamin
D absorption studies comparing different bariatric procedures, while controlling for UVB exposure and dietary vitamin D intake and accounting for the potential contribution from adipose tissue, are needed to enhance our understanding of issues affecting vitamin D status and optimal dosing in the RYGB patient population.

Adipose tissue vitamin D3 content before RYGB
We were able to quantify vitamin D3, in both SAT and VAT; as might be expected, most subjects did not have detectable concentrations of vitamin D2. Limited data exist on SAT and VAT vitamin D concentrations. Similar to our findings, vitamin D3 has been detected in SAT (6,17) and VAT (17) in patients undergoing RYGB. We found a correlation between vitamin D concentrations in VAT and SAT. Additionally, in the small number of subjects for whom we had adipose samples, the vitamin D3 concentration in VAT was greater by 19% than that observed in SAT for all subjects. It is tempting to conclude from these results that vitamin D3 may be preferentially stored in VAT compared with SAT. This is an important area for further research. Because we were interested to know, at a maximum, how much vitamin D might theoretically be stored in total whole body FM, we took each of the 13 subject’s VAT vitamin D concentration and multiplied it by their total FM. In this way, we estimated the average total FM vitamin D content to be 115,353 ± 33,628 IU (mean ± SEM; range: 7,120-373,043 IU). If one assumes the daily consumption rate of 4,000 IU day\(^{-1}\), as posited by Heaney et al. (33), needed to maintain normal serum 25(OH)D, that amount would represent on average a 29 day vitamin D supply (and based on the range of data for our subjects, it could be as low as 2 days and as high as 93 days). This provides evidence against the sequestration hypothesis.

We also attempted to evaluate the relationship between serum 25(OH)D and adipose vitamin D concentrations. Although we did not find a statistically significant relationship between serum and adipose concentrations, it is interesting to note that, among the seven subjects for whom we had both serum 25(OH)D and adipose vitamin D concentrations, the one with the highest serum 25(OH)D also had the highest SAT and VAT vitamin D concentrations. On the other hand, the subject with the lowest serum 25(OH)D (which was 23 ng mL\(^{-1}\), an adequate concentration) did not have the lowest adipose vitamin D concentrations in this small subsample. Larger scale studies are needed to clarify and confirm the difference in SAT and VAT vitamin D concentrations, and to further elucidate the relationship between adipose and serum vitamin D compartments.

Vitamin D intake before and after RYGB
In this study, we found improved vitamin D intake after RYGB. It was apparent that the subjects in our study attempted to adhere to the supplement regimen, as at the week 52 visit, 87% of their vitamin D intake was from supplements (vs. 64% at baseline). The importance of vitamin D supplementation in this patient population is highlighted by a component of the surgery that promotes food restriction. A small gastric pouch is created by the surgeon, which promotes early satiety (31,34) and thereby decreases intake (34). This alteration of the gastrointestinal tract leads to drastic reduction in food intake, from 2300 (35) to 2900 (36) kcal per day before surgery to an average intake of 1,200-1,400 kcal per day at least 12 months post-RYGB (35,37). Generally, dietary intake of vitamin D is minimal considering that few foods are naturally rich in the vitamin (e.g., oily fish) or are fortified (e.g., milk); however in a population that is already restricting their food intake, supplementation is especially key for optimal vitamin D intake. We found that subjects in our study compensated for the reduced ability to consume vitamin D containing foods by taking supplements. Nonetheless, there was a broad range of vitamin D intake in our subjects, therefore caution is warranted when interpreting these results.

Relationships between serum 25(OH)D and anthropometrics
In our analyses, we found positive relationships between change in anthropometrics (FM, body weight, BMI, and %EWL) and change in serum 25(OH)D, in analyses that took into account other factors that could affect postoperative 25(OH)D concentration. The mechanisms linking increased serum 25(OH)D concentration with decreased FM/body weight are not well understood. In those with obesity-related conditions that could potentially affect vitamin D metabolism (e.g., NAFLD), weight loss may ameliorate the condition, possibly resulting in improved serum 25(OH)D concentrations. Indeed, with FM/body weight loss, the degree of obesity-related inflammation generally improves, as measured by the reduction of proinflammatory cytokines (e.g., IL-6) (38). Recent research indicates that serum 25(OH)D and IL-6 are inversely related (39). Therefore, with weight loss-mediated improvement in inflammation (e.g., decreased IL-6 levels), reduced turnover of vitamin D may occur, resulting in increased circulating levels. However, this relationship has not been extensively evaluated and additional prospective studies are needed.

In our study, both weight and FM loss were associated with a rise in serum 25(OH)D concentration, with weight loss having the strongest association. In four separate models, we assessed change in serum 25(OH)D levels after RYGB in relation to changes in anthropometrics after accounting for potential confounders (vitamin D intake, age, and study visit). Weight loss, FM loss, BMI decrease, and %EWL were significantly associated with change in serum 25(OH)D levels. Importantly, body weight had the most significant association with change in serum 25(OH)D.

In all of the adjusted models, vitamin D intake was not significantly associated with serum 25(OH)D levels. Arunabh et al. also did not find strong correlations between vitamin D intake and serum 25(OH)D levels (9). Our vitamin D intake data were highly variable at all visits, which could have affected our ability to detect a relationship between it and change in vitamin D status in our models. In addition, vitamin D intake in our subjects may not have been high enough to promote a change in serum 25(OH)D. Continued research on the optimal oral vitamin D dosage in these patients is warranted.

Our findings appear to be consistent with a recent study (40) that suggests an alternative to the earlier adipose sequestration hypothesis (7). Utilizing linear and hyperbolic modeling methods, Drincic et al. (40) reported that a greater volume of distribution in obese compared to normal weight individuals accounts for the lower serum 25(OH)D concentrations in obesity and thus obese individuals likely require higher doses to reach normal concentrations. Our data certainly support this more recent line of thinking. Utilizing the average VAT vitamin D concentration in 13 subjects (48 ± 14 ng g\(^{-1}\), which is 1,936 ± 541 IU kg\(^{-1}\); mean ± SEM), we can extrapolate the total vitamin D content anticipated to be released using the average fat
mass loss for the total sample of 37 kg. This amount (71,621 IU) would have released vitamin D at a rate of 1,377 IU week \(^{-1}\). This observation suggests that the release of vitamin D from adipose stores is clearly not the primary contributor to the rise of serum vitamin D following RYGB. Furthermore, by using our body weight data we can independently evaluate the hyperbolic modeling equation proposed by Drincic et al. (40). From Figure 1 in Drincic et al., one can calculate the fitted constants \(a = 58.01715\) and \(b = 56.92308\), for serum 25(OH)D in ng/mL and body weight in kg, respectively. Figure 1 in the present article depicts observed serum 25(OH)D data at all visits plotted with the estimate from the Drincic et al. paper. Observed mean change in serum 25(OH)D from Baseline to the week 52 visit was similar to the predicted value (+9.9 ng mL\(^{-1}\) vs. +5.5 ng mL\(^{-1}\); \(P = 0.090\)), and this suggests that the Drincic et al. model adequately predicts serum 25(OH)D levels.

Limitations of this study include a small sample comprised solely of Caucasian women, the lack of direct sun exposure data, and statistical modeling that only highlights associations. We were also not able to measure gut vitamin D absorption, and the intake levels may not reflect actual amounts of vitamin D absorbed. Although we measured vitamin D in SAT and VAT at baseline, our study would have been stronger had we been able to perform similar analyses after RYGB. In addition, although subjects met with a registered dietitian at their pre- and postoperative visits at the Weight Loss Surgery Center and were educated about the importance of taking a vitamin D supplement, compliance was an issue, as determined from diet records. Larger prospective studies in a racially diverse population that assess FM, vitamin D intake, sun exposure, and vitamin D concentrations in adipose tissue before and after RYGB are needed.

The strengths of this study include its prospective study design with data collection before and at several time points for 1 year after RYGB. We also measured FM, vitamin D intake, and SAT and VAT vitamin D concentrations, which have not been commonly reported in this patient population. Our study employed methods and a research approach similar to that of Holick et al (17). Recently Holick’s group reported on serum 25(OH)D changes after RYGB and characterized vitamin D in various adipose depots (17). Our dietary intake data appear to be stronger based on methodology; we followed a strict protocol utilizing 3-day dietary records that involved intensive subject training and review by dietitian-supervised staff. Furthermore, we have actual FM data obtained through the deuterium dilution method. We also conducted a more robust statistical analysis that included adjusted models which allowed us to account for additional potential factors that might impact serum 25(OH)D concentrations.

The results of this study suggest a need for randomized clinical trials to not only define optimal treatment strategies in this patient population, but to also understand how normalization of serum 25(OH)D levels could be beneficial for outcomes related to traditional and nontraditional roles for vitamin D in human health. As the obese population grows and more individuals seek bariatric surgery, these research questions will be of considerable importance to investigate. In summary, this line of research has particular relevance to clinicians in obesity surgery because it further underscores the importance of comprehensive nutrition management and education with regard to vitamin D.

From a clinical perspective our data suggest that weight and FM loss may promote increased serum 25(OH)D concentration postoperatively, and release of vitamin D from adipose is not likely to be the primary contributing factor. We based this conclusion on actual SAT and VAT adipose vitamin D concentrations and total body FM data. We further utilized our FM data to independently evaluate the hyperbolic model, proposed by Drincic et al. (40) to describe the relationship between body size and serum 25(OH)D concentrations.
in obese individuals. On the basis of our analyses, we conclude that the volume of distribution appears to be an important contributing factor to serum 25(OH)D concentrations in obese individuals.

Acknowledgments

We thank the study participants for their commitment to this study and the team at the Weight Loss Surgery Center and the GCRC at the University of Minnesota for ongoing support of this study. We thank Dr. Michael Jensen, Charles Ford, and Jaime Gransee at the Mayo Clinic for assistance with the deuterium analyses, and Dr. Barbara McCloskey at Thomas Jefferson University for assistance with the 25(OH)D assays. We also thank Dr. Dale Schoeller for input on the TBW method.

References

1. Goldner WS, Stoner JA, Thompson J, et al. Prevalence of vitamin D insufficiency and deficiency in morbidly obese patients: a comparison with non-obese controls. Obes Surg 2008;18:145–150.
2. Holick MF. Vitamin D: a D-lightful health perspective. Nutr Rev 2008;66: S182–S194.
3. Ross AC, Taylor CL, Yaktine AL, et al. Dietary reference intakes for calcium vitamin D. Washington DC: National Academies Press; 2011.
4. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911.
5. Priemel M, von Domarus C, Klatte T, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25 – hydroxyvitamin D in 675 patients. J Bone Miner Res 2010;25:305.
6. Blum M, Dolnikowski G, Seyoum E, et al. Vitamin D(3) in fat tissue. Endocrine 2008;33:90–94.
7. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690–693.
8. Kremer R, Campbell PP, Reinhardt T, et al. Vitamin D status and its relationship to body fat, final height, and peak bone mass in young women. J Clin Endocrinol Metab 2009;94:67–73.
9. Arunabh S, Pollack S, Yeh J, et al. Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab 2003;88:157–161.
10. Kayaniyil S, Vierh R, Harris SB, et al. Association of 25(OH)D and PTH with circulating 25– hydroxyvitamin D in 675 patients. J Bone Miner Res 2010;25:305.
11. Arunabh S, Pollack S, Yeh J, et al. Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab 2003;88:157–161.
12. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009;19:1605–1611.
13. Smith BR, Schauer P, Nguyen NT. Surgical approaches to the treatment of obesity: bariatric surgery. Endocrinol Metab Clin North Am 2008;37:941–964.
14. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724–1737.
15. Lima MM, Pareja JC, Alegré SM, et al. Acute effect of roux-en-y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic-hyperinsulinenic clamp. J Clin Endocrinol Metab 2010;95:3871–3875.
16. Lin E, Armstrong-Moore D, Liang Z, et al. Contribution of adipose tissue to plasma 25-hydroxyvitamin D concentrations during weight loss following gastric bypass surgery. Obesity (Silver Spring) 2010;18:588–594.
17. Panyothin P, Biancuzzo RM, Lu Z, et al. Vitamin D in adipose tissue and serum 25-hydroxyvitamin D after Roux-en-Y gastric bypass. Obesity (Silver Spring) 2011;19:2228–2234.
18. Coupaye M, Puchaux K, Bogard C, et al. Nutritional consequences of adjustable gastric banding and gastric bypass: a 1-year prospective study. Obes Surg 2009;19: 56–65.
19. DiGiorgi M, Daud A, Inabnet WB, et al. Markers of bone and calcium metabolism following gastric bypass and laparoscopic adjustable gastric banding. Obes Surg 2008;18:1144–1148.
20. Gehrer S, Kern B, Peters T, et al. Fewer nutrient deficiencies after laparoscopic sleeve gastrectomy (LSG) than after laparoscopic Roux-Y gastric bypass (LRYGB)—a prospective study. Obes Surg 2010;20:447–453.
21. Riedt CS, Brolin RE, Sherrell RM, et al. True fractional calcium absorption is decreased after Roux-en-Y gastric bypass surgery. Obesity (Silver Spring) 2006;14:1940–1948.
22. Carlin AM, Rao DS, Yager KM, et al. Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial. Surg Obes Relat Dis 2009;5:444–449.
23. Phillips KM, Byrdwell WC, Exler J, et al. Development and validation of control materials for the measurement of vitamin D3 in selected U.S. foods. J Food Comp Anal 2008;21:527–534.
24. Levitt DG, Beckman LM, Mager J, et al. Comparison of DXA and water measurements of body fat following gastric bypass surgery and a physiological model of body water, fat, and muscle composition. J Appl Physiol 2010;109:786–795.
25. Schoeller DA. Hydrometry. In Roche AF, Heymsfield SB, Lohman TG, eds. Human body composition. Champaign, IL: Human Kinetics; 1996; p 25–43.
26. Ernst B, Thurnheer M, Schmid SM, et al. Seasonal variation in the deficiency of 25-hydroxyvitamin D(3) in mildly to extremely obese subjects. Obes Surg 2009;19:180–183.
27. Dalc cranale L, Oliveira CP, Faistuch J, et al. Long-term nutritional outcome after gastric bypass. Obes Surg 2010;20:181–187.
28. Fish E, Beverstein G, Olson D, et al. Vitamin D status of morbidly obese bariatric surgery patients. J Surg Res 2010;164:198–202.
29. Pietrokovski GA. Vitamin D—the steroid hormone prescription for every patient. Minn Med 2003;86:43–45.
30. Hines C Jr. Vitamins. Absorption and malabsorption. Arch Intern Med 1978;138:619–621.
31. Buchwald H. Consensus Conference Panel. Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis 2005;1:371–381.
32. Aarts E, van Groningen L, Horst R, et al. Vitamin D absorption: consequences of gastric bypass surgery. Eur J Endocrinol 2011;164:827–832.
33. Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2010;20:37:1201-20:37:1204.
34. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 2007;133:2221–2271.
35. Bobbioni-Harsch E, Huber O, Morel P, et al. Factors influencing energy intake and body weight loss after gastric bypass. Eur J Clin Nutr 2002;56:551–556.
36. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardio- vascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683–2693.
37. Beckman LM, Beckman TR, Silver MD, et al. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery. J Parenter Enteral Nutr 2011;35:169–180.
38. Moschen AR, Molnar C, Geiger S, et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin-6 and tumor necrosis factor alpha expression. Gut 2010;59:1259–1264.
39. Jabloński KL, Chonchol M, Piers G, et al. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 2011;57:63–69.
40. Drincic A, Armas LA, Van Dien E, et al. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity 2012;20:1444–1448.